INTRODUCTION: Minimal change @entity1985 (MCNS) is a common form of @entity1985 in @entity1 and young adults. We investigated its clinical presentations, @entity134 responsiveness, subsequent clinical course and patterns of relapse in older adults in whom it was diagnosed after the age of 50 years. METHODS: The clinical records of renal @entity1 followed-up in a single out @entity1 clinic were retrieved and those @entity1 with biopsy-proven MCNS were included. @entity1 in the 18-50-year age range (Group A) at the time of biopsy were compared with those older than 50 years (Group B) with regard to baseline demographic data, clinical features and outcome of treatment. RESULTS: In all, 50 @entity1 were studied, 35 in Group A (age at diagnosis: 38.8+/-11.91 years) and 15 in Group B (age at diagnosis: 70+/-6.85 years), with an overall follow-up duration of 72.08+/-63.42 months. Group B had a higher prevalence of @entity101 and lower @entity1011 clearance at presentation, but the values of @entity1011 clearance for both groups were comparable with age-matched controls. One @entity1 from Group B and two from Group A had spontaneous remission. Complete remission was achieved in 9.09, 45.45, 90.91 and 100% of Group B @entity1 and 15.63, 62.5, 87.5 and 93.75% of Group A @entity1 after 2, 4, 8 and 16 weeks of @entity134 therapy, respectively. The median time to complete remission and the duration of @entity134 treatment were similar for both groups. From Group B five @entity1 and 22 @entity1 from Group A relapsed during follow-up (P=0.055), with similar proportions of each group being early relapsers or frequent relapsers. The average number of relapses was 2.06 episodes for Group A, compared with 0.87 episodes for group B (P=0.062). Second agents were used in 20 Group A and four Group B @entity1 (P=0.048). Complications of treatment were more common in Group A. None of the @entity1 developed doubling of serum @entity1011 during follow-up. CONCLUSIONS: Clinical presentations of older @entity1 with MCNS were similar to younger @entity1 apart from the age-related decline of renal function and higher prevalence of @entity101 . Both groups have similar @entity134 responsiveness, but older @entity1 tend to have fewer relapses and require fewer second agents for treatment of relapses.

Idiopathic minimal change nephrotic syndrome in older adults: XXXX responsiveness and pattern of relapses.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'patient'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome']
@entity134 :: (CHEBI:35341,Chemical) :: ['steroid']
